Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Interim Results

Thumbnail
October 15, 2020

For Roche the pandemic giveth and taketh away

Thumbnail
August 25, 2020

Orthopaedics companies’ nightmare quarter

The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.

Article image
Vantage logo
July 31, 2020

Gilead unleashes the remdesivir blockbuster bulls

Article image
Vantage logo
July 30, 2020

Covid-19 deals different fates in the Parp world for Glaxo and Astra

Article image
Vantage logo
July 23, 2020

A poor quarter for Roche leads to muted expectations

Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.

Article image
Vantage logo
May 21, 2020

Covid-19 takes a toll on medtech’s first quarter

Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.

Article image
Vantage logo
May 18, 2020

Covid-19 excitement masks Sorrento’s disastrous capital structure

Article image
Vantage logo
May 13, 2020

Big Pharma remains bullish in the face of Covid-19

So far so good, as much of pharma shrugs off the full-year impact of Covid-19.

Article image
Vantage logo
May 01, 2020

Resmed’s sales jump thanks to Covid-19 and the FDA

Article image
Vantage logo
April 16, 2020

New Covid-19 test and a decent first quarter buoy Abbott

Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.

Article image
Vantage logo
April 14, 2020

J&J’s short, sharp Covid-19 hit could still prove best case

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Vantage logo
January 19, 2021

The pandemic releases its grip on clinical trials

Vantage logo
January 21, 2021

2020 drug approvals rise despite Covid-19

Vantage logo
January 20, 2021

Glaxo joins the Covid-19 delay queue

Vantage logo
January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.